We have previously described a hominid-specific long non-coding RNA, MORT (also known as , Gene ID: ), which is expressed in all ZNF667-AS1 100128252 normal cell types, but epigenetically silenced during cancer-associated immortalization of human mammary epithelial cells. Initial analysis of The Cancer Genome Atlas (TCGA) showed that 15 of 17 cancer types, which represent the 10 most common cancers in women and men, display DNA methylation associated silencing in a large fraction of their tumors. In MORT this study we analyzed expression and DNA methylation state in the MORT remaining 16 TCGA cancer types not previously reported. Seven of the 16 cancer types showed DNA methylation linked silencing in a large MORT fraction of their tumors. These are carcinomas (cervical cancer, and cancers of esophagus, stomach, and bile duct), and the non-epithelial tumors mesothelioma, sarcoma, and uterine carcinosarcoma. Together with the findings from our previous report, expression is silenced by aberrant MORT DNA methylation in 22 of 33 of TCGA cancer types. These 22 cancers include most carcinoma types, blood derived cancers and sarcomas. In conclusion, results suggest that the gene is one of the most common epigenetic MORT aberrations seen in human cancer. Coupled with the timing of gene MORT silencing during epithelial cell immortalization and its occurrence early in in vitro the temporal arc of human carcinogenesis, this provides strong circumstantial evidence for a tumor suppressor role for . MORT Lukas Vrba ( )
Introduction
MORT was originally found as a transcript silenced during in vitro immortalization of human mammary epithelial cells 1 . Like a significant majority of lncRNAs, MORT's molecular function remains enigmatic. The MORT gene is specific to higher primates, is expressed in all normal human cell types, and MORT RNA is located predominantly in the cytoplasm 1 . Analysis of MORT expression and the DNA methylation state of its promoter in 17 cancer types from The Cancer Genome Atlas (TCGA) 2 , which represent the 10 most frequent cancers in males and females, showed MORT is epigenetically silenced in 15 of 17 these cancers 1 . Based on the data from the original in vitro study 1 , we predicted epigenetic MORT silencing occurs early in human carcinogenesis and therefore could be seen in premalignant lesions, such as ductal carcinoma in situ of the breast and colonic adenomas. We used data from clinical samples from published genomic data sets 3-8 to address this possibility, and indeed, MORT loss occurs prior to or at the stage of pre-malignancy and not thereafter 9 . Taken together these facts suggest that MORT transcript has a tumor suppressive role and is not simply an epigenetic "passenger error."
Since our previous analysis of MORT in TCGA datasets was not exhaustive and only reported on 17 out of 33 TCGA cancer types, the goal of this short study was to extend our earlier work and complete the analysis of MORT DNA methylation associated gene silencing in the final 16 TCGA cancer types.
Methods
We integrated the MORT expression level and the DNA methylation state of its promoter region using TCGA data as described before 1 . The Illumina HiSeq RNA-seq and HumanMethylation450 DNA methylation data for samples of 16 TCGA cancer types listed in Table 1 were downloaded from the GDC data portal. The data were analyzed in the R programming environment, version 3.4.2 10 . The mean RNA-Seq rpkm values for the two exons constituting the MORT RNA were plotted against the mean DNA methylation beta value of the 7 CpGs from the MORT promoter region for the individual samples of each cancer type. The Spearman correlation coefficient rho between the MORT RNA level and the DNA methylation of MORT promoter was calculated using the function cor.test.
Results and discussion
Seven of sixteen analyzed cancer types (CESC, CHOL, ESCA, MESO, SARC, STAD, and UCS) show strong MORT silencing by DNA methylation (Figure 1 ). The negative correlation rho between MORT expression and DNA methylation in these cancers is below -0.5; the DNA methylation level in some tumor samples of these cancers exceeds 0.5 beta (> 50% DNA methylation), and a large fraction of the tumor samples in these cancer types have very low to no MORT expression level ( Figure 1 ). The correlation of MORT expression and promoter DNA methylation in the remaining nine cancer types is also negative; however, the maximum level of the DNA methylation of MORT promoter in some of these cancers is either very low (UVM), or a very few tumor samples have MORT silenced (ACC, KICH, OV, and THYM), and some of the cancer types (GBM, LGG, PCPG, and TGCT) do not appear to display MORT gene silencing ( Figure 1 ).
The analysis presented shows DNA methylation associated MORT gene silencing in 7 of 16 TCGA cancer types. Compared to the 17 TCGA cancer types presented in our original study, 1 most the 16 cancer types presented here lack their respective normal tissues samples and some of them have lower amounts of tumor samples (Table 1) . Nevertheless, the distribution of MORT expression and DNA methylation data in tumor samples clearly indicates MORT silencing in multiple cancer types (Figure 1 ).
Cervical tumors (CESC) have high proportion of MORT silencing ( Figure 1) ; more than 75% of 304 cervical tumor samples have MORT promoter DNA hypermethylated and MORT silenced. Using TCGA data, a recent study found MORT downregulated in cervical cancer
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, but surprisingly did not report on or hypothesize potential mechanisms for this transcriptional repression. Here we confirm and extend their initial analysis of MORT silencing in cervical cancer and show further that this silencing is strongly linked to aberrant DNA methylation of the MORT promoter.
Combined together with the findings from our previous report 1 , Table 2 shows MORT is silenced by DNA methylation in 9 . This could likely be extended to all 22 cancer types with the high fraction of MORT negative samples and the high correlation between MORT RNA level and MORT promoter DNA methylation, where MORT likely plays a tumor suppressive role. The other 11 cancer types, with a little to no MORT silencing, might have tumor suppressive pathway, where MORT is involved, interrupted elsewhere and/or MORT may play some additional vital role in tissues these tumors originate from -e.g. prostate, thyroid, brain, testes, or ovary -since these tissues typically have the highest levels of MORT RNA 1 .
In summary, our findings show that the MORT gene is one of the most common epigenetic aberrations seen in human cancer. Coupled together with MORT silencing occurring early in the temporal arc of human carcinogenesis it strongly supports a tumor suppressive role for MORT.
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SUGGESTIONS FOR IMPROVEMENT:
-The authors make a bold statement that "the MORT gene is one of the most common epigenetic aberrations seen in human cancer". This statement is not supported by the data presented. In order to make a statement of this level, the authors would have to provide comparisons to other documented genes that undergo a high frequency of epigenetic alteration.
-This statement becomes more difficult to make when considering that several of the tumors present do not have normal counterparts for comparison. We therefore do not know if those tissue types whether the DNA methylation is abnormal or typical for the tissue type.
-Authors should consider revising some of the scales on the graphs in Figure 1 to highlight the lack of methylation (for example, in testicular germ cell tumors). Similarly, the cutoff for methylation could be shown by a dotted line or similar feature.
-The location of methylation relative to the MORT gene would be informative. Of the tumor types that are methylated, are the same regions methylated across types?
-The authors should be cautious not to overstate their conclusions throughout the text since the conclusions are speculative without experiments to support their statements. Nevertheless, these correlations present interesting speculation and avenues for further investigations. 
